

ASX Announcement

31 August 2026

Monash IVF Group Limited (ASX: MVF)

Board succession and renewal

Monash IVF Group Limited (ASX:MVF) announces the next steps in the Board renewal and succession program it initiated in 2024. These include the appointment of Ms Catherine West as Chair-elect to succeed Mr Richard Davis as Chair, the appointment of Mr Gerd Schenkel as an independent Non-Executive Director, and the retirement of long-serving directors.

At the Company's 2025 Annual General Meeting, Mr Davis outlined the renewal process and announced he would stand for re-election to continue to oversee the transition – including the appointment of a new permanent CEO and new Directors – before retiring in 2026. The program has included the appointments of Ms Cathy Aston (February 2024) and Dr Dwayne Crombie (November 2025) as independent Non-Executive Directors, and of Dr Victoria Atkinson as CEO in January 2026.

Mr Davis will retire from the Board on 28 October 2026 after more than 12 years as Chair, and will be succeeded by Ms West, a Director since September 2020. Dr Richard Henshaw and Mr Neil Broekhuizen will also retire after more than 12 years' service, Dr Henshaw on 28 October 2026 and Mr Broekhuizen on 31 August 2026. Mr Schenkel will be appointed to the Board with effect from 1 September 2026 and will stand for election at the next Annual General Meeting. Further information on Ms West's and Mr Schenkel's experience is set out below.

Following these changes, the Board will comprise Ms West as Chair, Ms Zita Peach (a Director since October 2016), Ms Aston, Dr Crombie, Mr Schenkel and Dr Atkinson. The Board is progressing a search for one further Non-Executive Director.

Mr Davis said "I am pleased that Catherine has agreed to succeed me as Chair. Her experience, knowledge of Monash IVF and strong contribution to the Board position her well to lead the Company through its next phase, and I look forward to working with her to support an orderly transition."

We are also delighted to welcome Gerd to the Board. His technology, digital transformation and customer experience expertise will complement the Board's existing skills as Monash IVF continues to invest in innovation and execute its strategy.

I also want to pay tribute to Richard Henshaw and Neil Broekhuizen, valued colleagues since the Company listed, and thank them for their wise counsel and commitment over many years."

Ms West said "On behalf of the Board, I thank Richard Davis for his leadership in steering Monash IVF and thank Dr Richard Henshaw and Neil Broekhuizen for their significant contribution – each having given dedicated service to the Company since its IPO in 2014."

I am honoured to be appointed Chair-elect, and warmly welcome Gerd and the expertise he will bring to the Board. FY26 has been a year of significant change for Monash IVF, with encouraging momentum established in the second half. We enter FY27 as a stronger organisation, with renewed operational focus and a clear strategic direction articulated in the refreshed Nurture 2030 strategy. I am looking forward to taking on the role of Chair at this important point in the Group's journey and to working with the Board, Victoria and the rest of the management team to build on the momentum and deliver sustainable long-term value."

Mr Schenkel said *"It is a privilege to join the Board of Monash IVF at an important time for the Company. Having spent my career in technology, digital and customer-focused businesses in regulated sectors, I look forward to working with the Board and management as Monash IVF strengthens its digital capability and the experience it delivers for its patients."*

Authorised by the Board of Directors.

For further information please contact:

Rebecca Dean

General Counsel & Company Secretary
Monash IVF Group
T: +61 3 9420 8235

About Ms Catherine West

Ms West is an experienced ASX listed company Chair and non-executive director, and has been a Director of Monash IVF since September 2020. She was Chair of Nine Entertainment Co. (NEC), retiring from the board in November 2025 after almost 10 years as a director, and is currently a Non-Executive Director of Peter Warren Automotive Group (PWR), where she chairs the People and Remuneration Committee. She is Chair of the National Institute of Dramatic Art (NIDA) and Chair of the Board of Governors of Wenona School, and is a former Director of Southern Phone Company. Ms West previously spent over 30 years in executive roles in the media, entertainment and telecommunications sectors in Australia, the UK, Europe and Asia, including 17 years on the senior leadership team of Sky plc.

About Mr Gerd Schenkel

Mr Schenkel is an experienced ASX listed company director and senior executive with expertise in strategy, digital transformation, technology, customer experience and governance in regulated, consumer-facing businesses. He has previously held senior executive roles with Tyro Payments, Telstra and National Australia Bank, including UBank. He has previously served on the Board of Helia Group Limited (HLI) and Credit Clear Limited (CCR) and is currently a Director of Bondi Growth Advisers Pty Ltd (BGAD Consulting).